Universite Rene Descartes in Paris, France, in 1971. The majority of his professional life was spent at SANDOZ, and then as Senior Director and Group Leader at Novartis Pharma, in Basel, Switzerland.
His primary research interest was salmon calcitonin, particularly in the development of first, the nasal, and then the oral, formulations for this drug for usage in the metabolic bone diseases including osteoporosis, and in osteoarthritis. In this regard, he collaborated widely with other investigators in the field of metabolic bone disease, particularly in Europe and the USA. His travel itinerary was legendary as he traveled widely to enthusiastically discuss salmon calcitonin and metabolic bone disease.
A gentle man, loyal to his friends and colleagues, he is buried with his family in Israel. He will be greatly missed. Shalom.
